OncoMatch/Clinical Trials/NCT07198074
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Is NCT07198074 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Pembrolizumab for advanced endometrial carcinoma.
Treatment: Bevacizumab · Carboplatin · Paclitaxel · Pembrolizumab — This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: TP53 mutation
P53 IHC with aberrant staining pattern (aberrant p53 expression is consistent with mutant TP53). TP53 mutation by next-generation sequencing will also be accepted
Disease stage
Required: Stage III, IVA, IVB
Stage III and stage IVA endometrial cancers (with measurable disease), Stage IVB endometrial cancer (with or without measurable disease), or Recurrent endometrial cancer (with or without measurable disease)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy (pembrolizumab)
NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy)
Cannot have received: anti-PD-L1 therapy
NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy)
Cannot have received: anti-CTLA-4 therapy
NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy)
Cannot have received: antiangiogenic therapy (bevacizumab)
NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy) or bevacizumab (or other antiangiogenic therapy)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 8 g/dl
Kidney function
Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); AST and ALT ≤ 3 x institutional ULN
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 8 g/dl; Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula; Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN; cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mercy Cancer Center - Carmichael · Carmichael, California
- Mercy San Juan Medical Center · Carmichael, California
- Mercy Cancer Center - Elk Grove · Elk Grove, California
- Mercy Cancer Center - Rocklin · Rocklin, California
- Mercy Cancer Center - Sacramento · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify